HGH Fragment 176-191
Also known as: HGH Frag, Fragment 176-191
Molecular Identifiers
Molecular Formula
C80H127N23O24S2
CAS Number
66004-57-7
PubChem CID
172966176Molecular Weight
1817.12 Da
Overview
Synthetic peptide corresponding to amino acids 176-191 of human growth hormone. Promotes lipolysis without effect on insulin or IGF-1.
The main clinical interest around HGH Fragment 176-191 is its selective lipolytic effect: it stimulates triglyceride breakdown in adipose tissue and inhibits lipogenesis, without the systemic effects of full-length GH on insulin, IGF-1, or tissue growth. This profile makes it attractive in fat-loss protocols, especially for stubborn abdominal fat, without the risk of insulin resistance or unwanted hypertrophy.
HGH Fragment 176-191 currently has no regulatory approval from any agency (FDA, EMA, ANVISA). It is most often dispensed by compounding pharmacies as off-label use, in cycles of 12 weeks or more, with subcutaneous administration fasted or pre-cardio. WADA lists GH fragments as substances prohibited at all times for competitive athletes.
Among GH fragments, it is most often compared with AOD 9604: both derive from the C-terminal portion of GH and aim to isolate the lipolytic effect without the anabolic effects of the whole hormone, but HGH Frag 176-191 is the unmodified native sequence, while AOD 9604 is a version with an added N-terminal tyrosine (Tyr-hGH 177-191) that provides greater stability.
FLRIVQCRSVEGSCGF Phe-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe Half-life
~30 minutes
Administration Route
Subcutaneous
Category
Metabolic & Fat Loss
Mechanism of Action
- Direct lipolysis in adipose tissue
- No effect on insulin or IGF-1
- Inhibition of lipogenesis
- No anabolic activity on muscle tissue
Dosage Protocol
Data compiled from the literature. This does not constitute medical advice.
| Parameter | Value |
|---|---|
| Dose | 250-500 mcg per injection |
| Frequency | 1-2 times per day |
| Timing | Morning fasted, pre-cardio |
| Duration | 12+ weeks |
Reported Side Effects
Adverse effects described in the literature. Severity and frequency vary between individuals.
- Injection site pain
- Local redness
- Mild headache
- Hypoglycemia (rare)
Product Properties
| Purity | >98% |
| Appearance | White lyophilized powder |
| Solubility | Soluble in water and bacteriostatic water |
| Source | Solid-phase peptide synthesis (SPPS) |
| Storage | Lyophilized: -20°C for up to 2 years, 2-8°C for up to 6 months. Reconstituted: 2-8°C for up to 4 weeks. Protect from light and moisture. Avoid repeated freeze-thaw cycles. |
Presentations & Preparation
Vials of HGH Fragment 176-191 found in the research market:
Reconstitution
- Diluent: Bacteriostatic water
- Volume: 2 ml per vial
- Inject the diluent slowly against the vial wall
- Gently swirl until fully dissolved
- Never shake
Storage
- Lyophilized: Refrigerated 2-8°C
- Reconstituted: Refrigerated 2-8°C (up to 30 days)
- Protect from direct light
- Do not freeze after reconstitution
Scientific Studies
Published studies on HGH Fragment 176-191.
Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment
Heffernan MA, Thorburn AW, Fam B, Summers R, Conway-Campbell B, Waters MJ, Ng FM
The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice
Heffernan MA, Jiang WJ, Thorburn AW, Ng FM
Related Peptides
5-Amino-1MQ
50 mg per capsule · 1-2 times daily
Adipotide
0.03 mg/kg body weight (Phase 1 trial starting dose) · Once daily
AICAR
0.1 mg/kg/min by intravenous infusion (CABG trial dose) · Single continuous infusion
AOD 9604
300-600 mcg per injection · Once daily
Cagrilintide
1.2-4.5 mg per week (subcutaneous) · Once weekly
Dulaglutide
0.75-4.5 mg per week (subcutaneous) · Once weekly